Ent-11α-hydroxy-15-oxo-Kaur-16-en-19-Oic-Acid induces apoptosis of human malignant cancer cells

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1730-1737

  Li, Ming Yue ^a   Liang, Nian Ci ^b   Chen, George G ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

5F; Akts; Bcl 2 family; MAPK; Mitochondria mediated pathway; NF B; PsL

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; APOPTOSIS INDUCING FACTOR; BH3 PROTEIN; CASPASE; CISPLATIN; CYTOCHROME C; DOXORUBICIN; ENT 11 ALPHA HYDROXY 15 OXO KAUR 16 EN 19 OIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAURENOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P53; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAKE FERN; CANCER CELL; CANCER SURVIVAL; CELL DEATH; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; METABOLIC REGULATION; NONHUMAN; STOMACH CANCER; THYROID CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DITERPENES; HUMANS; MITOCHONDRIA; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84879313768     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545623     Document Type: Article

References (121)

1. Ding HS. The Chinese Medicinal Crytogam, 1st edition Shanghai. Shanghai Publishing House of Science and Technology 1982; pp 104.
2. Murakami T, Tanaka N. Occurrence, structure and taxonomic implications of fern constituents. Progress in the Chemistry of Organic Natural Products 1988; 54: 284.
3. Yang H, Dou QP. Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer. Curr Drug Targets 2010; 11: 733-44.
4. Li J, Liang N, Mo L, Zhang X, He C. [Comparison of the cytotoxicity of five constituents from Pteris semipinnata L. in vitro and the analysis of their structure-activity relationships]. Acta Pharmaceutica Sinica 1998; 33: 641-644.
5. Zhang X, Cui L, Nobutoshi T, Liang NC. The active constituents and antitumor action of Pteris semipinnata. Chinese Pharmaceutical Journal 1997; 32: 37-38.
6. Zhang X, Li JH, He CW, Liang NC. Study on the diterpenoid constituents and anticancer action of pteris semipinnata. Chinese Pharmaceutical Journal 1999; 34: 512-514.
7. Li JH, He CW, Liang NC, MO LE, Zhang X. Effects of antitumor compounds isolated from Pteris semipinnata L on DNA topoisomerases and cell cycle of HL-60 cells. Acta Pharmacologica Sinica 1999; 20: 541-545.
8. Deng YF, Liang N, Liang T. Analysis of the Diterpenoids in the extract of Pteris Semipinnata L by HPLC-APCI-MS. Acta Pharmaceutica Sinica 2002; 37: 444-446.
9. Hall IH, Lee KH, Mar EC, Starnes CO, Waddell TG. Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones. J Med Chem 1977; 20: 333-337.
10. Liang T, Gou ZP, Liang NC. Studies on the Difference in Content of an Antitumor Component 5F in Pteris semipinnata L. Journal of China Pharmaceutical University 2002; 33: 401-403.
11. Liang T, Qin Y, Deng Y, Liang N. Determination of an antitumor component 5F in Pteris Semipinnata by HPLC. Chinese Pharmaceutical Journal 2002; 37: 209-211.
12. Lan L, Deng Y, Liang N, Mo L. A new method for isolating and purifying the active cpmpound 5F from Pteris Semipinnate L. Journal of Guangdong medical College 2003; 21: 100-101.
13. Deng Y, Liang N. Study on extraction and separation of diterpenoids from Pteris semipinnata. Chinese Pharmaceutical Journal 2004; 39: 742-744.
14. Deng Y, Liang N. Investigation on chromatogram of Diterpenoids in Pteris semipinnate by HPLC-APCI-MS. Journal of Chinese Medicinal Materials 2005; 28: 278-280.
15. Dian L, Liang N. Study on extraction process in Pteris semipinnate L. China Pharmaceutics 2007; 16: 24-25.
16. Lv Y, Chen GG, Gong XL, Wu K, Liang N. Studies on quality standard of PsL 5F injections. China Journal of Chinese Materia Medica 2008; 33: 2343-2346.
17. Lu YN, Wu K, Liang N, Chen GG. LC Method for Quantification of ent-11a-Hydroxy-15-oxo-kaur-16-en-19-oic Acid in Rabbit Plasma: Validation and Application to a Pharmacokinetic Study. Chromatographia 2009; 70: 1599-1603.
18. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
19. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.
20. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687.
21. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
22. Antonsson B. Mitochondria and the Bcl-2 family proteins in apoptosis signaling pathways. Mol Cell Biochem 2004; 256-257: 141-155.
23. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003; 195: 158-167.
24. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
25. Smets LA. Programmed cell death. apoptosis; and response to anticancer drugs. Anticancer Drugs 1994; 5: 3-9.
26. Li MY, Leung J, Kong AW, et al. Anticancer efficacy of 5F in NNK-induced lung cancer development of A/J mice and human lung cancer cells. J Mol Med 2010; 88: 1265-1276.
27. Chen GG, Leung J, Liang NC, et al. Ent-11α-hydroxy-15-oxokaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα. Invest New Drugs 2012; 30(6): 2210-2218.
28. Liu Z, Ng EK, Liang NC, et al. Cell death induced by Pteris semipinnata L. is associated with p53 and oxidant stress in gastric cancer cells. FEBS Lett 2005; 579: 1477-1487.
29. Vlantis AC, Lo CS, Chen GG, et al. Induction of laryngeal cancer cell death by Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid. Head Neck 2010; 32: 1506-1518.
30. Liu ZM, Chen GG, Vlantis AC, et al. Cell death induced by ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid in anaplastic thyroid carcinoma cells is via a mitochondrial-mediated pathway. Apoptosis 2005; 10: 1345-1356.
31. Chen GG, Liang NC, Lee JF, et al. Over-expression of Bcl-2 against Pteris semipinnata L-induced apoptosis of human colon cancer cells via a NF-kappa B-related pathway. Apoptosis 2004; 9: 619-627.
32. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590-8607.
33. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
34. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998; 1378: F21-F59.
35. Stellman SD, Takezaki T, Wang L, et al. Smoking and lung cancer risk in American and Japanese men: an international case-control study. Cancer Epidemiol Biomarkers Prev 2001; 10: 1193-1199.
36. Stepanov I, Upadhyaya P, Carmella SG, et al. Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol Biomarkers Prev 2008; 17: 1764-1773.
37. Akopyan G, Bonavida B. Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol 2006; 29: 745-752.
38. Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005; 32: 169-176.
39. Felip E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 2007; 7: 261-268.
40. Foley JF, Anderson MW, Stoner GD, et al. Proliferative lesions of the mouse lung: progression studies in strain A mice. Exp Lung Res 1991; 17: 157-168.
41. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, Anderson MW. Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res 1992; 52: 3164-3173.
42. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATPdependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
43. Potokar M, Milisav I, Kreft M, Stenovec M, Zorec R. Apoptosis triggered redistribution of caspase-9 from cytoplasm to mitochondria. FEBS Lett 2003; 544: 153-159.
44. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15 Suppl 4: 42-52.
45. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
46. Mott JL, Gores GJ. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology 2007; 46: 906-911.
47. Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 2006; 44: 151-157.
48. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001; 34: 55-61.
49. Watanabe J, Kushihata F, Honda K, et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004; 135: 604-612.
50. Chen GG, Lai PB, Chan PK, et al. Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur J Cancer 2001; 37: 1695-1702.
51. Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm Res 1997; 47: 145-157.
52. Sherman SI. Thyroid carcinoma. Lancet 2003; 361: 501-511.
53. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130: 1028-1034.
54. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994; 74: 1348-1354.
55. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
56. Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs 2011; 30: 1367-1384.
57. Lacueva J, Gallego J, Díaz-González JA. Updating controversies on the multidisciplinary. Clin Transl Oncol 2010; 12: 677-685.
58. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
59. Bosset JF, Lorchel F, Mantion G, et al. Radiation and chemoradiation therapy for esophageal adenocarcinoma. J Surg Oncol 2005; 92: 239-245.
60. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
61. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27-39.
62. D'Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-816.
63. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
64. Sikalidis AK, Varamini B. Roles of Hormones and Signaling Molecules in Describing the Relationship Between Obesity and Colon cancer. Pathol Oncol Res 2011; 17: 785-790.
65. Franceschi S, Munoz N, Bosch XF, Snijders PJ, Walboomers JM. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996; 5: 567-575.
66. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
67. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008; 27: 6194-206.
68. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897-907.
69. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
70. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-928.
71. Feo F, Frau M, Tomasi ML, Brozzetti S, Pascale RM. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med (Maywood) 2009; 234: 726-736.
72. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitinproteasome pathway. Genes Dev 1995; 9: 1586-1597.
73. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629-3639.
74. Cavin LG, Romieu-Mourez R, Panta GR, et al. Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology 2003; 38: 1540-1551.
75. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspasedependent downregulation of gp130 in multiple myeloma. Oncogene 2003; 22: 8386-8393.
76. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004; 101: 2351-2362.
77. Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004; 6: 390-400.
78. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 959-971.
79. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 513-520.
80. Shi YH, Ding WX, Zhou J, et al. Expression of X-linked inhibitorof-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 2008; 48: 497-507.
81. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.
82. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435: 29-34.
83. Tamatani M, Mitsuda N, Matsuzaki H, et al. A pathway of neuronal apoptosis induced by hypoxia/reoxygenation: roles of nuclear factor-kappaB and Bcl-2. J Neurochem 2000; 75: 683-693.
84. Tamatani M, Che YH, Matsuzaki H, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem 1999; 274: 8531-8538.
85. Kirito K, Watanabe T, Sawada K, et al. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem 2002; 277: 8329-8337.
86. Kurland JF, Kodym R, Story MD, et al. NF-kappaB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 2001; 276: 45380-45386.
87. Feuillard J, Schuhmacher M, Kohanna S, et al. Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 downregulation in Epstein-Barr virus-transformed B lymphocytes. Blood 2000; 95: 2068-2075.
88. Khoshnan A, Tindell C, Laux I, et al. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 2000; 165: 1743-1754.
89. Omar HA, Sargeant AM, Weng JR, et al. Targeting of the Aktnuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol 2009; 76: 957-968.
90. Qiao L, Zhang H, Yu J, et al. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther 2006; 17: 280-290.
91. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13: 1076-1082.
92. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005; 56: 46-54.
93. Cianfrocca R, Muscolini M, Marzano V, et al. RelA/NF-kappaB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ 2008; 15: 354-363.
94. Simmons MJ, Fan G, Zong WX, et al. Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist. Oncogene 2008; 27: 1421-1428.
95. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466.
96. Du J, Chen GG, Vlantis AC, et al. The nuclear localization of NFkappaB and p53 is positively correlated with HPV16 E7 level in laryngeal squamous cell carcinoma. J Histochem Cytochem 2003; 51: 533-539.
97. Vancurova I, Wu R, Miskolci V, Sun S. Increased p50/p50 NFkappaB activation in human papillomavirus type 6-or type 11-induced laryngeal papilloma tissue. J Virol 2002; 76: 1533-1536.
98. Guo Y, Liu J, Xu Z, Sun K, Fu W. HLA-B gene participates in the NF-kappaB signal pathway partly by regulating S100A8 in the laryngeal carcinoma cell line Hep2. Oncol Rep 2008; 19: 1453-1459.
99. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63: 1400-1402.
100. Wei Q, Sheng L, Shui Y, et al. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008; 15: 1193-1201.
101. Kourelis K, Sotiropoulou-Bonikou G, Vandoros G, et al. Coordinated upregulation of COX-2 and NF-kappaB is a steady feature of laryngeal carcinogenesis. ORL J Otorhinolaryngol Relat Spec 2007; 69: 181-189.
102. Sarkar FH, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008; 13: 2950-2959.
103. Li MY, Yip J, Hsin MK, et al. Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis. Eur Respir J 2008; 32: 911-923.
104. Liu Y, Chen GG, Lu Y, et al. Effects of 5F on IκKβ, IκB, p65, and p50 mRNA expression of non-small lung cancer NCI-H460 cells. Chinese Traditional and Herbal Drugs 2010; 41: 435-439.
105. Garrouste F, Remacle-Bonnet M, Fauriat C, et al. Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells-evidence for a NF-kappaB-dependent survival mechanism. Cell Death Differ 2002; 9: 768-779.
106. Wenzel U, Kuntz S, Brendel MD, Daniel H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 2000; 60: 3823-3831.
107. Li L, Lv Y, Liu Y, et al. Apoptosis in HepG2 cells induced by Pteris semipinnata extract 5F invovles p53 activation and VEGF inhibition. Chinese Traditional and Herbal Drugs 2010; 41: 73-77.
108. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
109. Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001; 20: 8009-8018.
110. Nagamine M, Okumura T, Tanno S, et al. PPAR gamma ligandinduced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci 2003; 94: 338-343.
111. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23: 100-108.
112. Li M, Lee TW, Mok TS, et al. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 2005; 96: 760-774.
113. Nguyen TT, Tran E, Nguyen TH, et al. The role of activated MEKERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004; 25: 647-659.
114. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000; 22: 818-826.
115. Chen CH, Wang WJ, Kuo JC, et al. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO Journal 2005; 24: 294-304.
116. Li M, Lee TW, Yim AP, Mok TS, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptorgamma-and ERK-dependent in human non-small lung cancer cells. J Cell Physiol 2006; 209: 428-438.
117. Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 2005; 24: 3285-3296.
118. Millet A, Bettaieb A, Renaud F, et al. Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. Gastroenterology 2002; 123: 235-246.
119. Caivano M. Role of MAP kinase cascades in inducing arginine transporters and nitric oxide synthetase in RAW264 macrophages. FEBS Lett 1998; 429: 249-253.
120. Guan Z, Baier LD, Morrison AR. p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1beta. J Biol Chem 1997; 272: 8083-8089.
121. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.